Abeona Therapeutics Inc. (0H7R.L)

3.4180 -4.2220 (-55.26%) At close: 06:40PM BST

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103
United States
646 813 4701
https://www.abeonatherapeutics.com

Sector(s): 
Industry: 
Full-time employees: 84

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Vishwas Seshadri M.B.A., Ph.D.	President, CEO & Director	1.49M	N/A	1977
Mr. Joseph Walter Vazzano CPA	Chief Financial Officer	920.85k	N/A	1985
Dr. Brendan M. O'Malley J.D., Ph.D.	Senior VP & General Counsel	802.95k	N/A	1970
Mr. Brian Kevany Ph.D.	Senior VP, CTO & CSO	N/A	N/A	N/A
Mr. Gregory Gin	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Alison Hardgrove	Vice President of Human Resources	N/A	N/A	N/A
Mr. Jon Voss	VP & Head of Quality	N/A	N/A	1960
Mr. Dmitriy Grachev M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A
Dr. Madhav Vasanthavada M.B.A., Ph.D.	Senior VP, Chief Commercial Officer & Head of Business Development	N/A	N/A	N/A
Mr. Carl Denny	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Corporate governance

Abeona Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.